Background: It is difficult to treat the patients of lung cancer with malignant pleural effusion(MPE). Recently, the effect of the chemotherapy including Bevacizumab regimen is suggested. Aims: We assessed the effect of the chemotherapy of Carboplatin, Paclitaxel and Bevacizumab(CPB) regimen for lung cancer patients with MPE. Methods: Since 2011 to 2016, 21 patients with MPE received first line chemotherapy with CPB regimen. We assessed treatment effect of the patients for rate of decreased pleural effusion, progression free survival (PFS) and overall survival (OS). And compared with 20 patients without MPE received first line chemotherapy with CPB regimen. Result: 21 patients with MPE, histology(all adenocarcinoma), male (15 patients), median age (69, 52-77 years), ECOG performance status 0-1 (19 patients). Pleural effusion decreased in 18 patients(85.7%). PFS median was 6.1 months and OS median was 9.5 months. 17 patients had positive histologic or cytologic evidence. Compared with positive and negative histologic or cytologic evidence, no statistical difference was shown in PFS (positive 6.1 months vs negative 5.5 months, p=0.939) and OS (positive 8.8 months vs negative 9.4 months, p=0.931). Compared with no MPE patients, no statistical difference were shown in PFS and OS (no MPE 7.2 months vs MPE 6.1 months, p=0.261 and no MPE 13.8 months vs MPE 9.5 months, p=0.256) Conclusion: Compared with no MPE and MPE, MPE tended to poor prognosis, but there was no statistical difference in PFS and OS. These results suggest the chemotherapy including Bevacizumab regimen has good cotrol for MPE.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.